Pharmaceutical Intermediates Docetaxel Raw Material Docetaxel Powder Purity Docetaxel

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Docetaxel
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Docetaxel
• Name: Docetaxel Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: 99%
• Specific: COA
• Test Method: HPLC, UV
• CAS: 114977-28-5
• Mf: C43h53no14
• MW: 807.88
• Melting Point: 186-192
• Boiling Point: 900.5
• Stability: Stable
• Shelf Life: 2 Years
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical Intermediates Docetaxel Raw Material Docetaxel Powder Purity Docetaxel

Product Description

Product Details

Product Name	Docetaxel
Assay	99%
Test Method	HPLC
Appearance	White Crystalline Powder
CAS NO	114977-28-5
Molecular Formula	C43H53NO14

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel has an approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline-based chemotherapy and failed to stop cancer progression or relapsed.
Administered as a one-hour infusion every three weeks generally over a ten cycle course, docetaxel is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule agent.

Application&Function

1.It is a clinically well established anti mitotic chemotherapy medication (that is, it interferes with cell division).
2.It is used mainly for the treatment of breast, ovarian, and non-small cell lung cancer.
3.It has an FDA approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline based  chemotherapy and failed to stop cancer progression or relapsed. An European  approval  docetaxel for use in hormone-refractory prostate cancer.
4.It is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule.

Specification